



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07C 217/52, 217/54, 323/26, 225/20, 211/40, A61K 31/13, 31/135	A1	(11) International Publication Number: WO 95/26327 (43) International Publication Date: 5 October 1995 (05.10.95)
(21) International Application Number: PCT/EP95/00964 (22) International Filing Date: 14 March 1995 (14.03.95) (30) Priority Data: 9406043.1 26 March 1994 (26.03.94) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BROWN, Thomas, Henry [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). HARLING, John, David [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). ORLEK, Barry, Sidney [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). (74) Agent: FLORENCE, Julia; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SUBSTITUTED CYCLOALKYLAMINE DERIVATIVES AND THEIR USE AS CALCIUM CHANNEL ANTAGONISTS		
<div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		
(57) Abstract <p>The use of a compound of formula (I), wherein X represents O, S, C=O or a bond; p and q independently represent 0-4; R¹ and R² each independently represent hydrogen, C₁-alkyl, C₃-cycloalkyl or C₃-cycloalkylC₁-alkyl; n is 1, 2, 3 or 4; and Ar represents phenyl optionally substituted by 1 to 3 substituents selected from: halo, C₁-alkyl, C₁-alkoxy, C₁-alkylenedioxy, trifluoromethyl, trifluoromethoxy, CN, NO₂, amino, mono- or di-alkylamino and Ph(Alk¹)_rY(Alk²)_s where Ph is optionally substituted phenyl, Y is a bond, oxygen or a carbonyl group, Alk¹ and Alk² independently represent C₁-alkyl which may be straight or branched and r and s are independently 0 or 1, provided that the length of (Alk¹)_rY(Alk²)_s does not exceed 5 atoms, and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for the treatment of a disorder wherein a calcium channel antagonist is indicated, e.g. ischaemic stroke. Certain novel compounds within formula (I) are also claimed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


SUBSTITUTED CYCLOALKYLAMINE DERIVATIVES AND THEIR USE AS CALCIUM CHANNEL ANTAGONISTS

The present invention relates to carbocyclic derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular as calcium channel antagonists, e.g. for the treatment of ischaemic stroke.

5 Stroke is reportedly the third most common cause of death in the developed world. Current therapies for ischaemic stroke are limited and have a number of disadvantages, such as the risk of exacerbating haemorrhage. There is therefore a need for new and improved treatments for ischaemic stroke.

10 DE 3231912 describes aminocyclohexylmethylaniline derivatives; no pharmaceutical activity is ascribed to the compounds. DE 4010325 discloses phenoxy carbocyclic derivatives which are said to have insecticidal activity and intermediates therefor. Teller and Jarboe (J. Med. Chem. (1982) 25 (3) 227) describe *cis*- and *trans*-2-(3,4-dimethoxybenzyl)cyclopentylamine, said to be transient hypotensive agents.


15 EPA 200101 describes therapeutic compositions comprising as active ingredient one of a very broad class of compounds of the formula:



20 wherein Ar and Ar₁ are independently phenyl, naphthyl, or a nitrogen, oxygen or sulphur ring; R₁, R₂ and R₃ are selected from a wide range of substituents; R₄ is also selected from a wide range of acyclic and cyclic substituents, including saturated and unsaturated carbocyclic and heterocyclic rings, which include *inter alia* cyclopentane and cyclohexane, substituted by (XR₆)_n where X is O, S or NR₈ (R₈ is H or lower alkyl), R₆ is *inter alia* H or lower alkyl and n is 0 or 1; Z, Z₁, Z₂ and Z₃ are independently a bond or an alkylene chain; Y is *inter alia* a bond, O, S or CO; and M is *inter alia* O. The more preferred
25 compounds are said to be those wherein Ar is quinoline and in the substituent (XR₆)_n X is O. The specification contains only a few examples or named compounds wherein R₄ is cyclohexyl or cyclopentyl and in each of them the ring is substituted by either a hydroxy or methoxy group. No compounds containing an amino-substituted, saturated, 4-7-membered carbocyclic ring are specifically named or exemplified. The compounds
30 described in EPA 200101 are said to be lipoxygenase inhibitors possessing anti-inflammatory and anti-allergic properties.

We have now found a distinct class of amino-substituted carbocyclic derivatives which represent a novel selection with respect to the compounds described in EPA 200101 and which surprisingly exhibit activity as calcium channel antagonists.

35 The present invention therefore provides in a first aspect the use of compounds of formula (I) :



Formula (I)

wherein

X represents O, S, C=O or a bond;

5 p and q independently represent 0-4;

R¹ and R² each independently represent hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl or

C₃₋₆cycloalkylC₁₋₄alkyl;

n is 1, 2, 3 or 4; and


Ar represents phenyl optionally substituted by 1 to 3 substituents selected from :

10 halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₂alkylenedioxy, trifluoromethyl, trifluoromethoxy, CN, NO₂, amino, mono- or di- alkylamino and Ph(Alk¹)_rY(Alk²)_s- where Ph is optionally substituted phenyl, Y is a bond, oxygen or a carbonyl group, Alk¹ and Alk² independently represent C₁₋₄alkyl which may be straight or branched and r and s are independently 0 or 1, provided that the length of (Alk¹)_rY(Alk²)_s does not exceed 5 atoms;

15 and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of a disorder wherein a calcium channel antagonist is indicated.

As indicated above certain compounds of formula (I) are believed to represent a novel selection with respect to EPA 200101. In a further aspect therefore the invention provides compounds of formula (IA):

20



Formula (IA)

wherein

X represents O, S, C=O or a bond;

25 p and q independently represent 0-4;

R¹ and R² each independently represent hydrogen, C₁₋₆alkyl C₃₋₆cycloalkyl or

C₃₋₆cycloalkylC₁₋₄alkyl;

n is 1, 2, 3 or 4; and

Ar represents phenyl optionally substituted by 1 to 3 substituents selected from :

30 halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₂alkylenedioxy, trifluoromethyl, trifluoromethoxy, CN, NO₂, amino, mono- or di- alkylamino and Ph(Alk¹)_rY(Alk²)_s- where Ph is optionally

substituted phenyl, Y is a bond, oxygen or a carbonyl group, Alk^1 and Alk^2 independently represent C_{1-4} alkyl which may be straight or branched and r and s are independently 0 or 1, provided that the length of $(\text{Alk}^1)_r\text{Y}(\text{Alk}^2)_s$ does not exceed 5 atoms, and salts thereof; provided that:

- 5 when X is O and p and q are 0, Ar is not phenyl substituted by p-fluorophenoxy, chloro or methyl, and when X is a bond and the sum of p and q is 1, Ar is not unsubstituted phenyl, or phenyl substituted by amino, methoxy, methyl or dimethylamino.

In a yet further aspect the present invention provides the use as a therapeutic agent of a compound of formula (IB) which is defined as for formula (I) above with the
 10 proviso that when X is O and p and q are 0, Ar is not phenyl substituted by chloro or methyl, and when X is a bond and the sum of p and q is 1, Ar is not unsubstituted phenyl, or phenyl substituted by amino, methoxy, methyl or dimethylamino.

In the compounds of formulae (I), (IA) and (IB) when Ar represents phenyl this is advantageously substituted by a group $\text{Ph}(\text{Alk}^1)_r\text{Y}(\text{Alk}^2)_s$. The sum of r and s is
 15 preferably zero or 1. Alk^1 and Alk^2 preferably independently represent CH_2 or when branched, $\text{C}(\text{H})(\text{CH}_3)$ or $\text{C}(\text{CH}_3)_2$. When Y is oxygen s is preferably zero and r is preferably zero or 1. When Y is a bond the sum of r + s is preferably 1 or 2, most preferably 1. When Y represents $\text{C}=\text{O}$, r and s are preferably both zero. It is preferred that only one of Alk^1 and Alk^2 represents a branched alkyl moiety; for example if Alk^1
 20 represents a branched group such as $\text{C}(\text{CH}_3)_2$ s is advantageously zero and Y represents oxygen or more preferably a bond.

Suitable substituents for the group Ph include halogen, C_{1-4} alkoxy, C_{1-4} alkyl, trifluoromethyl and trifluoromethoxy.

Particularly preferred substituents of the formula $\text{Ph}(\text{Alk}^1)_r\text{Y}(\text{Alk}^2)_s$ thus include
 25 benzyloxy, benzyl, benzoyl, phenoxy, 1-methyl-1-phenylethyl, 1-(4-fluorophenyl)-1-methylethyl and 4-fluorophenoxy.

In a particular embodiment of the invention each Alk^1 and Alk^2 independently represents a straight chain C_{1-4} alkyl group, provided that the total number of carbon atoms in Alk^1 and Alk^2 does not exceed 4. In this embodiment $\text{Ph}(\text{Alk}^1)_r\text{Y}(\text{Alk}^2)_s$ can
 30 be represented by a group $\text{Ph}(\text{CH}_2)_j\text{Y}^1(\text{CH}_2)_k$, wherein Ph is optionally substituted phenyl, Y^1 is oxygen, a carbonyl group or a bond and j and k each independently represent 0-4 provided that the sum of j+k is not greater than 4. Preferably j and k independently represent zero or 1, such that the sum of j and k does not exceed 1.

Particularly preferred substituents of the formula $\text{Ph}(\text{CH}_2)_j\text{Y}^1(\text{CH}_2)_k$ thus include
 35 benzyloxy, benzyl, benzoyl, phenoxy, and 4-fluorophenoxy.

Ar preferably represents phenyl substituted by benzyl, 1-methyl-1-phenylethyl, 1-(4-fluorophenyl)-1-methylethyl, benzyloxy, benzoyl, phenoxy or 4-fluorophenoxy.

X preferably represents a bond or oxygen atom, in which case the sum of p and q

is preferably from 1 to 3. When X is oxygen, p is preferably zero or 1 and q is preferably zero. When X is a bond the sum of p and q is preferably 1. Most preferably X is oxygen, p is 1 and q is zero.

R¹ and R² preferably independently represent hydrogen or C₁₋₆alkyl, eg
5 C₁₋₄alkyl, preferably methyl. Most preferably one of R¹ and R² represents hydrogen and the other represents hydrogen or methyl.

n is suitably 1 to 4, preferably n is 2.

Alkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched. Thus, a C₁₋₆alkyl group may be for example methyl,
10 ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as isopropyl or t-butyl.

In a particularly preferred selection of compounds of formula (I), n is 2, X is oxygen, p is zero or 1 (preferably 1) and q is zero, or X is a bond and the sum of p and q is 1, and Ar represents phenyl substituted by a group Ph(Alk¹)_rY(Alk²)_s where Ph is
15 phenyl optionally substituted by fluoro, Y is a bond, oxygen or a carbonyl group, Alk¹ and Alk² each independently represent CH₂ or C(CH₃)₂ and r and s each independently represent zero or 1 provided that the sum of r+s is not greater than 1 and further provided that when X is O and p and q are both 0, Ar is not phenyl substituted by p-fluorophenoxy. Most preferred values for X, p, q and Ar are as defined above.

20 It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts. Other non-
25 pharmaceutically acceptable salts eg oxalates, may be used for example in the isolation of final products and are included within the scope of this invention. Also included within the scope of this invention are solvates and hydrates of formula (I).

It will be appreciated that the compounds of formula (I) contain two or more asymmetric centres. Such compounds will exist as optical isomers (enantiomers). Both
30 the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. In particular it will be appreciated that the substituents on the carbocyclic nucleus may both lie on the same side with respect to the plane of the ring (*cis*-configuration) or on opposite
35 sides (*trans*-configuration). Both forms and all mixtures thereof are included within the scope of this invention.

In accordance with convention the (+) and (-) designations used herein indicate the direction of rotation of plane-polarised light by the compounds. The prefix (+)


indicates that the isomer is dextrorotatory (which can also be designated d) and the prefix (-) indicates the levorotatory isomer (which can also be designated l).

Particular compounds of the formula (I) include :

- (±) *cis*-1-methylamino-2-(4-benzyloxyphenoxy)cyclopentane;
 - 5 (±) *trans*-1-methylamino-2-(4-benzyloxyphenoxy)cyclopentane;
 - (±) *cis*-1-methylamino-2-(4-benzyloxybenzyl)cyclopentane;
 - (±) *cis*-1-amino-2-(4-benzyloxybenzyl)cyclopentane;
 - (±) *cis*-1-amino-2-(4-benzoylphenoxy)methyl)cyclopentane;
 - (±) *cis*-1-amino-2-(4-benzylphenoxy)methyl)cyclopentane;
 - 10 (±) *cis* 1-methylamino-2-(4-benzylphenoxy)methyl)cyclopentane;
 - (±) *cis*-1-amino-2-(3,4-dichlorophenoxy)methyl)cyclopentane;
 - (±) *cis* -1-Amino-2-[4-(4-fluorophenoxy)phenoxy)methyl]cyclopentane;
 - (±) *cis* -1-Amino-2-[4-(1-methyl-1-phenylethyl)phenoxy)methyl]cyclopentane;
 - (±) *cis* 1-Methylamino-2-[4-(1-methyl-1-phenylethyl)phenoxy)methyl]cyclopentane;
 - 15 (±) *cis* -1-Amino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxy)methyl]cyclopentane;
 - (±) *cis* -1-Methylamino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxy)methyl]-cyclopentane;
- and salts thereof.

- The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect, a process for the preparation of compounds of formula (I) which comprises :

(a) to prepare a compound of formula (I) wherein X is O and p and q are both 0, reaction of a compound of formula (II):




25

Formula (II)

wherein n and Ar are as hereinbefore defined with a compound R^1R^2NH wherein R^1 and R^2 are as hereinbefore defined;

- (b) to prepare a compound of formula (I) wherein R^1 and R^2 are both hydrogen, reduction of a compound of formula (III):


30



Formula (III)

wherein n, p, q, X and Ar are as hereinbefore defined and R³ is C₁₋₄alkyl or phenylC₁₋₄alkyl (e.g. benzyl);


- 5 (c) to prepare a compound wherein X is O or S reaction of a compound of formula (IV):



Formula (IV)

- 10 wherein R¹, R², p and n are as hereinbefore defined and X¹ is O or S, with a compound of formula L(CH₂)_qAr wherein L is a leaving group and q and Ar are as hereinbefore defined;

- (d) reaction of a compound formula (V):



Formula (V)

- 15 wherein R¹, R², p and n are as hereinbefore defined and L¹ is a group displaceable by a nucleophile, with a compound HX(CH₂)_qAr wherein X, q and Ar are as hereinbefore defined;

- (e) interconversion of a compound of formula (I) to a different compound of formula (I), e.g.

- 20 (i) where one of R¹ and R² is hydrogen and the other is alkyl, conversion to a compound of formula (I) wherein R¹ and R² are both alkyl, or
- (ii) where R¹ and R² are both hydrogen, conversion to a compound of formula (I) where at least one of R¹ and R² represent alkyl;
- (iii) conversion of a benzoyl substituent in the group Ar to benzyl, or to 1-methyl-1-phenylethyl;
- 25

and optionally after any of the above processes, forming a salt of formula (I).


Process (a) may be effected using a suitable reducing agent such as sodium cyanoborohydride, preferably in an inert solvent such as tetrahydrofuran, methanol or diethyl ether.

5 Reduction of a compound of formula (III) according to process (b) may be effected using a reducing agent such as lithium borohydride and trimethylsilyl chloride, lithium aluminium hydride or $\text{NaBH}_3(\text{OCOCF}_3)$ in an inert solvent such as an ether, e.g. diethyl ether or tetrahydrofuran. In general this process gives predominantly the *cis*-form of the product.

10 In process (c) the reaction between a compound of formula (IV) and $\text{L}(\text{CH}_2)_q\text{Ar}$ may be effected under conditions which depend on the nature of L and the value of q. For example when q is zero, L is preferably fluoro and the reaction is preferably effected in the presence of a strong base such as sodium hydride, and in a polar organic solvent such as dimethylsulphoxide or dimethylformamide. In this case the aryl group is preferably
15 substituted by an activating group such as benzoyl. When q is other than zero, L may be for example halo or preferably a sulphonic acid residue such as a tosylate or mesylate and the reaction may be carried out using standard conditions, in a solvent and optionally in the presence of a base, which solvent and base may, if desired be selected from those described above.

20 The reaction between a compound of formula (V) and $\text{HX}(\text{CH}_2)_q\text{Ar}$ in process (d) can take place under conditions which depend on the nature of L^1 and X. For example when L^1 is hydroxy, q is zero and X is oxygen or sulphur the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine. Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1; and J. Org. Chem.
25 1991, 56, 670-672). Alternatively the leaving group L^1 may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy in which case the reaction may be effected using standard conditions, in the presence or absence of solvent, optionally in the presence of a base.

30 Interconversions (i) and (ii) according to process (e) may be effected by alkylation of a compound (I) wherein one of R^1 and R^2 is hydrogen and the other is alkyl or where R^1 and R^2 are both hydrogen, using an appropriate alkylating agent such as an alkyl halide e.g. an alkyl bromide or iodide, in the presence of a base, such as potassium carbonate. The reaction may be carried out in a suitable solvent such as acetone.
35 Alternatively said compound of formula (I) may first be acylated, using for example an alkylhaloformate such as ethyl chloroformate, preferably in the presence of a tertiary amine such as triethylamine, or a carbonate such as di-*tert*-butyldicarbonate, in the presence of sodium hydroxide and a solvent such as dioxane, to provide a compound of formula (VI):



Formula (VI)

5

wherein n, p, q, X, Ar and R¹ are as hereinbefore defined and Alk is a C₁₋₄alkyl group; followed by reduction as described above. In a further method a compound of formula (I) may be subjected to reductive alkylation using an appropriate aldehyde (e.g. formaldehyde) or ketone, and a reducing agent such as sodium cyanoborohydride.

10

Reduction of a benzoyl substituent to benzyl according to (e)(iii) may be effected using e.g. sodium borohydride in trifluoroacetic acid. Conversion of the benzoyl group to a 1-methyl-1-phenethyl group can be effected by reaction with (CH₃)₂TiCl₂, for example in dichloromethane at -40°C (as generally described by Reetz et al. J.Org.Chem. 48 254 (1983)) and analogues can be prepared by variations of this method.

15

It will be appreciated that when any of the processes described herein involve a reduction step it will generally be desirable to employ reducing agents and conditions which do not affect or disturb substituents which are intended to be retained in the final product. The choice of appropriate reducing agents and conditions will be readily apparent to the skilled practitioner. Thus for example when Ar represents 3,4-

20

dichlorophenyl it is preferable to avoid the use of lithium aluminium hydride under forcing (e.g. reflux) conditions.

25


If necessary during any of processes (c), (d) and (e)(iii) when R¹ and R² both represent hydrogen the amino group may be protected using standard methods e.g. as a phthalimido group which may be removed at the end of the synthesis by treatment with hydrazine.

Processes (c) and (e) generally proceed with retention of the *cis* or *trans* configuration of the starting material.

A compound of formula (II) may be prepared using standard procedures analogous to those outlined in DE 4010325.

30

A compound of formula (III) may be prepared by reaction of a compound of formula (VII):



Formula (VII)

with a compound of formula $L^2(CH_2)_pX(CH_2)_qAr$ in the presence of lithium bis-(trimethylsilyl)amide in a solvent such as tetrahydrofuran.

Compounds of formula (IV) wherein X is O can be prepared using standard methods. For example the compound of formula (IV) in which n is 2, p is 1 and R^1 and R^2 are both hydrogen can be prepared by reduction, for example using lithium aluminium hydride, of the corresponding cis-2-amino-1-cyclopentane carboxylic acid which is commercially available.

When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.

An ischaemic event such as stroke results in disruption of the blood supply to the brain, depriving it of essential oxygen. A cascade of biochemical reactions ensues, a consequence of which is to permit the influx of calcium ions into the brain cells (neurons) via so-called Voltage Operated Calcium Channels (VOCCs) causing cell death. It is believed that agents which inhibit such calcium influx will minimise cell death and hence increase the potential for recovery.

Compounds of formula (I) have been found to exhibit high calcium influx blocking activity for example in neurons. As such the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans. For example, the compounds are expected to be of use in the treatment of ischaemia including for example stroke, anoxia, and traumatic head injury. They may also be of use in the treatment of migraine, visceral pain, epilepsy, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal.

In a further aspect of the invention there is therefore provided a method of treatment of conditions or diseases related to (e.g. caused or exacerbated by) the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Thus, for example, the present invention provides a method of treatment of ischaemia including for example stroke, anoxia or traumatic head injury which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.. The invention also provides a method of treatment of migraine, visceral pain, epilepsy, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease, and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt

thereof.

The present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition or disease related to the accumulation of calcium in the brain cells of a mammal.

Compounds of the present invention will preferably be of use in the treatment of ischaemic stroke.

For use in medicine, the compounds of formula (I) are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a novel compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

The compounds of formula (I) may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.

The compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

Both liquid and solid compositions may contain other excipients known in the

pharmaceutical art, such as cyclodextrins.

Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.

Each dosage unit for oral administration contains preferably from 1 to 250 mg
5 (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.

The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, e.g. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg,
10 preferably between 0.1 mg and 60 mg, e.g. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Alternatively the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400 mg per day. Thus, the total daily dosage by oral administration will be in the range 1
15 to 2000 mg and the total daily dosage by parenteral administration will be in the range 0.1 to 400 mg. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more. It will be appreciated that the precise dosage and timing will be at the discretion of the physician and will depend amongst other factors on the severity of the condition to be treated. However, in general the first dose of a
20 compound of the invention will preferably be administered as soon as possible following an ischaemic event, eg within 12 hours, preferably within 6 hours.

If desired a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination or concurrently with one or more other therapeutic agents, for example a thrombolytic agent such as anistreplase, streptokinase or a tissue
25 plasminogen activator; an excitatory amino acid antagonist such as an NMDA antagonists; a free radical inhibitor; or a calpain inhibitor.

BIOLOGICAL DATA

Ca²⁺ Current Measurement

Cell preparations

- 5 Sensory neurons from dorsal root ganglia were dissociated from 1 day old rat pups (Ford et al, Developmental Brain Research, 22 (1985), 55-65). Cells were plated out onto glass coverslips and used within 3 days to permit effective voltage clamp of Ca²⁺ currents. Superior cervical ganglion neurons were isolated and cultured following a method modified from Marrion et al, Neurosci. Lett., 77, 55-60 (1987). Cells were plated onto
- 10 laminin coated plastic tissue culture dishes and incubated at 37°C until just prior to recording. Electrophysiological recordings were performed from 2 to 9 days after dissociation.

Solutions

- 15 The pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl₂, 4; ATP, 2; buffered to pH 7.2 with CsOH. Cells were bathed in a normal Tyrodes solution before establishment of whole cell recording when the bathing solution was changed to one allowing isolation of Ca²⁺ currents. The external solution for recording Ca²⁺ channel currents contained in mM: BaCl₂, 10; TEA-Cl, 130; glucose,
- 20 10; HEPES, 10; MgCl₂, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided. Compounds were dissolved in DMSO to make a 20 mM stock solution. At the drug concentration used the vehicle (0.1%) had no significant effect on Ca²⁺ currents. All experiments were performed at 21 to 24°C. Whole cell currents were
- 25 recorded using List EPC-7 amplifiers and stored, digitised for later analysis using PC based software similar to that described previously (Benham & Tsien, Journal of Physiology (1988), 404, 767-784).

Ca²⁺ currents

- 30 Peak voltage gated Ca²⁺ channel currents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba²⁺ as charge carrier. Currents were evoked from a holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to drifting holding potential. Some cells showed slow
- 35 rundown of current as is commonly seen when recording Ca²⁺ currents. The rundown rate was measured in control conditions and extrapolated through the time of drug application to derive a rundown corrected control value.

RESULTS**Dorsal Root Ganglion Cells**

Block by 20 μ M drug was assessed 3 minutes after drug application.

In this test compounds of Examples 1-3 and 5-7 gave percentage inhibition of plateau

5 Ca^{2+} current in the range 69 - 90 % at 20 μ M.

Superior Cervical Ganglion Cells

Once a constant calcium current had been recorded for 4 successive pulses (1 minute)

10 $10\mu\text{M}$ Nimodipine, a dihydropyridine, was applied to the cell to block L type calcium current. After three minutes 5 μ M drug was coapplied with 10 μ M Nimodipine for three minutes. Such drug application tested the block of the remaining, predominantly N type, calcium current.

In this test compounds of Examples 1-3 and 5-13 gave percentage inhibition of plateau Ca^{2+} current in the range 38 to 94 % at 5 μ M.

15

PHARMACEUTICAL FORMULATIONS

The following represent typical pharmaceutical formulations according to the present invention, which may be prepared using standard methods.

5

IV Infusion

Compound of formula (I)	1-40 mg
Buffer	to pH ca 7
Solvent/complexing agent	to 100 ml

10

Bolus Injection

Compound of formula (I)	1-40 mg
Buffer	to pH ca 7
Co-Solvent	to 5 ml

15

Buffer : Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.

20 Solvent : Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.

Tablet

Compound	1 - 40 mg
Diluent/Filler *	50 - 250 mg
25 Binder	5 - 25 mg
Disintegrant *	5 - 50 mg
Lubricant	1 - 5 mg
Cyclodextrin	1 - 100 mg

30 * may also include cyclodextrins

Diluent : e.g. Microcrystalline cellulose, lactose, starch

Binder : e.g. Polyvinylpyrrolidone, hydroxypropylmethylcellulose

Disintegrant : e.g. Sodium starch glycollate, croscopovidone

35 Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate.

Oral Suspension

	Compound	1 - 40 mg
	Suspending Agent	0.1 - 10 mg
	Diluent	20 - 60 mg
5	Preservative	0.01 - 1.0 mg
	Buffer	to pH ca 5 - 8
	Co-solvent	0 - 40 mg
	Flavour	0.01 - 1.0 mg
	Colourant	0.001 - 0.1 mg
10	Suspending agent : e.g. Xanthan gum, microcrystalline cellulose	
	Diluent :	e.g. sorbitol solution, typically water
	Preservative :	e.g. sodium benzoate
	Buffer :	e.g. citrate
15	Co-solvent :	e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin

The invention is further illustrated by the following non-limiting Preparations and Examples:

Preparation 1**(±) 2-(4-Benzyloxyphenoxy)-cyclopentanone**

To a mixture of 4-benzyloxyphenol (5g, 25mmol), potassium iodide (125mg), and potassium carbonate (4.48g, 32.5mmol) in 2-butanone (30ml) was added 2-chlorocyclopentanone (5.9g, 50mmol). The mixture was heated at reflux for 5 h, filtered and concentrated *in vacuo*. The residue was dissolved in diethyl ether and washed successively with 10% aqueous sodium hydroxide, water and brine. After drying over magnesium sulfate, solvents were removed *in vacuo* and the residue subjected to flash chromatography on silica gel eluting with 30% diethyl ether in hexanes to afford the title compound as a pale orange solid (2.4g).
¹H Nmr (CDCl₃) δ : 1.94 (2H, m), 2.15 (1H, m), 2.39 (3H, m), 4.49 (1H, t, J=7Hz), 5.01 (2H, s), 6.92 (4H, m), 7.37 (5H, m).

Preparation 2**(±) 2-(4-Benzyloxybenzyl)cyclopentanone oxime-o-benzyl ether**

To a solution of lithium bis-(trimethylsilyl)amide (34ml of a 1M solution in tetrahydrofuran, 34 mmol) in dry tetrahydrofuran (80ml) at -78°C under nitrogen was added a solution of cyclopentanone oxime-o-benzyl ether (5.72g, 30.2 mmol) in tetrahydrofuran (25ml). After 10 minutes a solution of 4-benzyloxybenzyl chloride (7.78g, 33.4 mmol) in tetrahydrofuran (25 ml) was added in one portion and the cooling bath removed. When the reaction mixture had reached room temperature, stirring was continued overnight before pouring into a large excess of water and extracting with diethyl ether (3 x 50 ml). The combined organic extracts were dried over sodium sulfate and volatiles removed *in vacuo*. The residue was subjected to column chromatography on silica gel eluting with 5% diethyl ether in hexanes to afford the title compound as a yellow oil (3.87g).
¹H Nmr (CDCl₃) δ : 1.31-1.92 (10H, m), 2.51 (1H, dd, J=8 and J=14Hz), 2.73 (1H, dd, J=6Hz and J=14Hz), 5.04 (2H, s), 6.87 (2H, d, J=8Hz), 7.10 (2H, d, J=8Hz), 7.35 (5H, m).

Preparation 3**(±) cis-1-(4-Benzyloxybenzyl)-2-tert-butoxycarbonylaminocyclopentane**

(±) cis-1-(4-Benzyloxybenzyl)-2-aminocyclopentane (470mg, 1.7 mmol) was dissolved in dioxane (25 ml) and cooled to 0°C. Aqueous 3M NaOH (560μl) and di-tert-butylidicarbonate (397μl, 1.7 mmol) were added, and the reaction stirred at room temperature for 3 h before pouring into water and extracting with diethyl ether

(3 x 40 ml). After drying over sodium sulfate, solvents were removed *in vacuo* and the residue recrystallised from ethanol/ hexanes to afford the **title compound** as an off white solid.

5

Preparation 4**(±) cis-1-Amino-2-hydroxymethylcyclopentane**

To a suspension of lithium aluminium hydride (3.68g, 0.097mol) in dry tetrahydrofuran (250ml) under argon was added portionwise (±) *cis*-2-amino-1-cyclopentanecarboxylic acid (2.50g, 0.019mol) . After stirring overnight at room temperature the reaction was quenched with wet diethyl ether followed by a minimum amount of water. The aluminium salts were removed by filtration and the precipitate was washed with 5% methanol in diethyl ether. The combined filtrate and washings were concentrated *in vacuo* to give an oil (1.9g) which was distilled on a Kugelrohr apparatus (150°C at 0.3 mm Hg) to give the **title compound** as a colourless oil (1.74g).

15

Preparation 5**(±) cis 1-Ethoxycarbonylamino-2-(4-benzylphenoxyethyl)cyclopentane**

To a solution of (±) *cis* 1-amino-2-(4-benzylphenoxyethyl)cyclopentane (0.9g, 3.20mmol) in dry diethyl ether (100ml) containing triethylamine (0.89ml, 6.4mmol) was added ethyl chloroformate (0.40ml, 4.16mmol) under argon. After stirring at room temperature for 2.5h the reaction was quenched with ice water and the pH of the aqueous layer was adjusted to 7 by addition of dilute hydrochloric acid. The organic layer was separated and the aqueous phase was extracted with diethyl ether (2x50ml). The combined organic layers were washed with brine , dried over sodium sulfate and concentrated *in vacuo* to give a pale yellow oil (1.16g) which was used in the next stage without further purification.

25

Preparation 6**(±) cis-1-Hydroxymethyl-2-phthalimidocyclopentane**

A mixture of (±) *cis* 1-amino-2-hydroxymethylcyclopentane (0.59g, 5.1mmol) and phthalic anhydride (0.76g, 5.1mmol) in xylene (40ml) was heated under argon at reflux using a condenser fitted with a Dean and Stark trap. After 1.5h the reaction was concentrated *in vacuo* and the residue was purified by column chromatography on silica gel eluting with diethyl ether to give the **title compound** as a pale yellow oil (1.0g).
¹H Nmr (CDCl₃) δ: 1.52-1.95 (3H, m), 1.98-2.20 (3H, m), 2.28-2.55 (2H, m), 3.45 (1H, m), 3.60 (1H, m), 4.75 (1H, q, J = 7Hz), 7.25 (2H, m), 7.30 (2H, m).

35

Preparation 7**(±) cis-1-[4-(1-Methyl-1-phenylethyl)phenoxy]methyl-2-phthalimidocyclopentane**

To an ice cold solution of (±) cis-1-hydroxymethyl-2-phthalimidocyclopentane (1.0g, 4.08mmol), triphenylphosphine (1.28g, 4.9mmol) and 4-cumylphenol (1.04g, 4.9mmol) in dry tetrahydrofuran (40ml) was added diethyl azodicarboxylate (0.77ml, 4.9mmol). The mixture was allowed to warm to room temperature and stirred for 48h. The reaction was poured into ice water (200ml) and extracted into diethyl ether (3x100ml). The combined extracts were washed with brine, dried over sodium sulfate and concentrated *in vacuo*. The resulting crude product was purified by chromatography on a silica gel column eluting with 10-40% diethyl ether in petroleum ether 40-60. Pooling of pure fractions afforded the title compound as a colourless oil (0.48g). Additional fractions afforded a further 0.76g of product which was slightly contaminated with 4-cumylphenol.

¹H Nmr (CDCl₃) δ: 1.45-2.16 (6H, s and 5H, m), 2.45-2.78 (2H, m), 3.88 (2H, m), 4.88 (1H, q, J = 8Hz), 6.48 (1H, d, J = 9Hz), 6.92 (2H, d, J = 9Hz), 7.08-7.30 (5H, m), 7.58-7.78 (4H, m)

Preparation 8**(±) cis-1-Ethoxycarbonylamino-2-[4-(1-methyl-1-phenylethyl)phenoxy]methylcyclopentane**

To a solution of (±) cis-1-amino-2-[4-(1-methyl-1-phenylethyl)phenoxy]methylcyclopentane (0.35g, 1.13mmol) in dry diethyl ether (30ml) containing triethylamine (0.31ml, 2.26mmol) was added a solution of ethyl chloroformate (0.18g, 1.70mmol) in diethyl ether (5ml). The reaction was stirred at room temperature for 2h and then poured into ice-water. The pH of the aqueous phase was adjusted to approximately 7 by the addition of dilute hydrochloric acid. The aqueous layer was separated and extracted with diethyl ether (2x30ml). The combined organic layers were washed with water followed by brine, then dried over sodium sulfate and concentrated *in vacuo* to give an oil (0.41g) which was used in the next stage without purification.

Preparation 9**4-[1-(4-Fluorophenyl)-1-methylethyl]phenyl methyl ether.**

To a solution of titanium tetrachloride (40ml of a 1M solution in dichloromethane, 40mmol) cooled to -40°C under argon was added dimethylzinc (20ml of a 2M solution in toluene, 40mmol), and the mixture was stirred for 10 minutes. A solution of 4-fluoro-4'-methoxybenzophenone (4.18g, 18.2mmol) in dichloromethane (20ml) was added whilst maintaining the temperature between -30°C and -40°C. The mixture was then allowed to

- warm to room temperature and stirred for 72h. The reaction was poured into ice cold water (100ml) and the aqueous phase extracted with diethyl ether (3x30ml). The combined organic phases were washed with sodium hydrogen carbonate followed by brine, then dried over sodium sulfate. After concentration *in vacuo* the residue was
- 5 subjected to column chromatography on silica gel eluting with 5% diethyl ether in 40-60 petroleum ether to afford the title compound as an oil (3.34g).
- ¹H Nmr (CDCl₃) δ: 1.64 (6H, s), 3.78 (3H, s), 6.80 (2H, d, J=9Hz), 6.92 (2H, t, J=9Hz), 7.10-7.22, 4H, m).

10

Preparation 10

4-[1-(4-Fluorophenyl)-1-methylethyl]phenol

- To a solution of 4-[1-(4-fluorophenyl)-1-methylethyl]phenyl methyl ether (3.34g, 13.67mmol) in chloroform (40ml) was added trimethylsilyl iodide (4.10g, 20.51mmol).
- 15 The solution was stirred under argon at 40°C for 18h, then cooled and poured into ice cold water (50ml). The aqueous phase was extracted with chloroform (6x20ml), and the combined organic layers were washed with sodium metabisulfite then brine, and dried over sodium sulfate. After concentration *in vacuo* the residue was subjected to column chromatography on silica gel eluting with 10-40% diethyl ether in 40-60 petroleum ether
- 20 to afford the title compound as an oil (2.4g).
- ¹H Nmr (CDCl₃) δ: 1.64 (6H, s), 4.81 (1H, s), 6.74 (2H, d, J=9Hz), 6.93 (2H, t, J=9Hz), 7.08 (2H, d, J=9Hz), 7.18 (2H, m).

Preparation 11

- 25 (±) *cis*-1-[4-(1-(4-Fluorophenyl)-1-methylethyl)phenoxy]methyl-2-phthalimido cyclopentane

- To an ice cold solution of (±) *cis*-1-hydroxymethyl-2-phthalimidocyclopentane (1.17g, 4.78mmol), triphenylphosphine (1.50g, 5.74mmol) and 4-[1-(4-fluorophenyl)-1-methylethyl]phenol (1.1g, 4.78mmol) in dry tetrahydrofuran (40ml) was added diethyl
- 30 azodicarboxylate (0.90ml, 5.74mmol). The mixture was allowed to warm to room temperature and stirred for 4 days. The reaction was worked up as described in Preparation 7. The resulting yellow foam was purified by chromatography on a silica gel column eluting with 20-40% diethyl ether in petroleum ether 40-60. Pooling of pure fractions afforded the title compound as a colourless oil (0.61g). Additional fractions afforded a
- 35 further 0.9g of product which was slightly contaminated with 4-[1-(4-fluorophenyl)-1-methylethyl]phenol.
- ¹H Nmr (CDCl₃) δ: 1.45-2.14 (6H, s and 5H, m), 2.43-2.78 (2H, m), 3.88 (2H, m), 4.88 (1H, q, J = 8Hz), 6.48 (2H, d, J = 9Hz), 6.90 (4H, m), 7.05 (2H, m), 7.60-7.78 (4H, m)

Preparation 12**5 (±) *cis*-1-Ethoxycarbonylamino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxyethyl] cyclopentane**

To a solution of (±) *cis*-1-amino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxyethyl] cyclopentane (0.58g, 1.77mmol) in dry diethyl ether (30ml) containing triethylamine (0.49ml, 3.54mmol) was added a solution of ethyl chloroformate (0.29g, 2.66mmol) in diethyl ether (5ml). The reaction was worked up as described in Preparation 8, and the
10 resulting yellow oil (0.62g) was used directly in the next stage.

Examples 1 and 2**15 (±) 1-Methylamino-2-(4-benzyloxyphenoxy)cyclopentane Hydrochloride (*cis* and *trans*)**

To a solution of 2-(4-benzyloxyphenoxy)cyclopentanone (1.76g, 6.2mmol) in methanol (150ml) was added methylamine hydrochloride (2.09g, 31mmol) and sodium cyanoborohydride (390mg, 6.2mmol) and the mixture stirred overnight at room temperature. The reaction mixture was concentrated *in vacuo* then partitioned between
20 diethyl ether and aqueous sodium bicarbonate. The organic phase was dried over sodium sulfate and concentrated *in vacuo*. The *cis* and *trans* diastereomers were separated by column chromatography on silica gel, eluting with 5% ethanol in chloroform and the corresponding HCl salts prepared.

25 More polar diastereomer (E1), m.p 149-150°C (from methanol/diethyl ether)
 ¹H Nmr (DMSO-d₆) δ : 1.63 (1H, m), 1.86 (4H, m), 2.13 (1H, m), 2.56 (3H, s), 3.51 (1H, m), 4.76 (1H, m), 5.06 (2H, s), 6.99 (4H, m), 7.41 (5H, m), 9.15 (2H, br. s).

 Less polar diastereomer (E2), m.p. 122.5-123.5°C (from methanol/diethyl ether)
30 ¹H Nmr (DMSO-d₆) δ : 1.76 (4H, m), 2.17 (2H, m), 2.59 (3H, s), 3.52 (1H, m), 4.85 (1H, m), 5.05 (2H, s), 6.95 (4H, m), 7.39 (5H, m), 9.45 (2H, br. s).

Example 3**35 (±) *cis*-1-methylamino-2-(4-Benzyloxybenzyl)cyclopentane Hydrochloride (E3)**

To a solution of lithium aluminium hydride (445mg, 12mmol) in dry tetrahydrofuran (25 ml) under nitrogen was added dropwise a solution of (±) *cis*-1-(4-benzyloxybenzyl)-2-tert-butoxycarbonylaminocyclopentane (446mg, 1.2mmol) in dry tetrahydrofuran (25ml). The reaction was heated at reflux for 3 h then cooled with an

ice/water bath and quenched with the minimum of water. The reaction was filtered and dried over sodium sulfate. Solvents were removed *in vacuo* and the residue subjected to column chromatography on silica gel eluting with 10% ethanol in chloroform to afford a colourless oil (146mg) which was converted to the HCl salt and crystallised to afford the title compound as a white solid, m.p. 183-184°C (from methanol/diethyl ether).

¹H Nmr (DMSO-d₆) δ: 1.28 (1H, m), 1.62 (4H, m), 1.97 (1H, m), 2.20 (1H, m), 2.37 (1H, m), 2.50 (3H, s), 2.94 (1H, dd, J=5Hz and J=15Hz), 3.10 (1H, m), 5.07 (2H, s), 6.93 (2H, d, J=8Hz), 7.16 (2H, d, J=8Hz), 7.40 (5H, m), 8.97 (2H, br. s).

Example 4

(±) *cis*-1-amino-2-(4-Benzyloxybenzyl)cyclopentane (E4)

To a solution of lithium aluminium hydride (312mg, 8.2 mmol) in dry diethyl ether (30ml) was added dropwise a solution of (±) 2-(4-benzyloxybenzyl) cyclopentanone oxime-o-benzyl ether (500mg, 1.4mmol) in diethyl ether (30ml). The mixture was allowed to stir at room temperature for 18 h before careful addition of a minimum amount of water to quench the reaction. The precipitated aluminium salts were filtered off and solvents removed *in vacuo*. The residue was subjected to column chromatography on silica gel eluting with 5% ethanol in chloroform to afford the title compound as a yellow oil (240mg).

¹H Nmr (CDCl₃) δ : 1.62 (4H, m), 2.30 (2H, m), 2.59 (1H, m), 3.12 (2H, m), 5.02 (2H, s), 5.12 (2H, s), 6.87 (2H, d, J=8Hz), 7.06 (2H, d, J=8Hz), 7.35 (10H, m).

Example 5

(±) *cis*-1-Amino-2-(4-benzoylphenoxymethyl)cyclopentane Hydrochloride (E5)

A solution of (±) *cis*-1-amino-2-hydroxymethylcyclopentane (1.1g, 0.01mol) in dry dimethyl sulfoxide (20ml), was treated with sodium hydride (0.36g of an 80% dispersion in oil; 0.012mol). After stirring for 2.5h at room temperature under argon a solution of 4-fluorobenzophenone (2.2g, 0.011mol) in dry dimethyl sulfoxide (10ml) was added dropwise. The mixture was warmed slowly to 50-60°C and held at this temperature for 15min. The reaction was quenched at ice temperature with glacial acetic acid (0.69ml, 0.012mol) and then concentrated *in vacuo* using co-distillation with xylene. The residue was partitioned between water (100ml) and diethyl ether (200ml). The aqueous layer was basified with potassium carbonate and further extracted with diethyl ether (3x200ml). The combined organic layers were dried over sodium sulfate and then concentrated *in vacuo* to give an oil. Purification by chromatography on silica gel eluting with 0-20% methanol in

diethyl ether afforded a light brown oil (2.4g). Treatment with ethereal HCl produced the hydrochloride salt which was recrystallised twice to give the title compound as a colourless solid. m.p. 182-185 °C (from methanol/diethyl ether).

- ¹H Nmr (CDCl₃) δ: 1.45-2.10 (6H, m), 2.49 (1H, m), 3.42 (1H, br m), 4.10 (1H, dd, J=10Hz and J=7Hz), 4.25 (1H, dd, J=10Hz and J= 8Hz), 7.05 (2H, d, J=9Hz), 7.35-7.90 (7H, m), 8.30 (3H, br s).

Example 6

10 (±) *cis*-1-Amino-2-(4-benzylphenoxy)methyl)cyclopentane Hydrochloride (E6)

- A solution of (±) *cis*-1-amino-2-(4-benzoylphenoxy)methyl)cyclopentane (2.0g, 6.78mmol) in dichloromethane (30ml) containing trifluoroacetic acid (40ml) was cooled in ice in an argon atmosphere and treated with a pellet of sodium borohydride (0.4g). After 1h a second pellet of sodium borohydride (0.4g) was added. The mixture was left stirring overnight at room temperature and then treated with a third pellet of sodium borohydride. After a further 6h the reaction was cooled in ice, treated with water and then basified with sodium hydroxide pellets. The mixture was extracted into diethyl ether and the combined extracts were concentrated *in vacuo* to give a brown oil. Purification on silica gel eluting with 10-20% methanol in diethyl ether afforded a light brown oil (1.3g). Extraction into pentane followed by treatment with ethereal HCl afforded the hydrochloride salt which was crystallised to give the title compound as a colourless solid. m.p. 181-183 °C (from methanol/diethyl ether).

- ¹H Nmr (CDCl₃) δ: 1.30-1.90 (6H, m), 2.25 (1H, m), 3.24 (1H, br m), 3.86 (2H, s), 3.92 (1H, dd, J=10Hz and J= 6Hz), 4.08 (1H, dd, J=10Hz and J=7Hz), 6.92 (2H, d, J=9Hz), 7.03 (2H, d, J= 9Hz), 7.10-7.30 (5H, m), 8.20 (3H, br s).

Example 7

(±) *cis* 1-Methylamino-2-(4-benzylphenoxy)methyl)cyclopentane Hydrochloride (E7)

- To a suspension of lithium aluminium hydride (0.65g, 17.0mmol) in dry diethyl ether (75ml) under argon was added dropwise a solution of (±) *cis* 1-ethoxycarbonylamino-2-(4-benzylphenoxy)methyl)cyclopentane (1.13g, 3.2mmol) in dry diethyl ether (25ml). After stirring overnight at room temperature the reaction was quenched with wet diethyl ether followed by a minimum amount of water. The aluminium salts were removed by filtration and the filtrate was concentrated *in vacuo* to give a pale yellow oil (0.93g). Extraction into pentane followed by treatment with ethereal HCl afforded the hydrochloride salt which was crystallised to give the title compound as a colourless solid. m.p. 183-185 °C (from methanol/diethyl ether).

¹H Nmr (CDCl₃) δ: 1.50-2.20 (6H, m), 2.60 (overlapping signals: 3H, s and 1H, m), 3.43 (1H, m), 3.90 (2H, s), 4.05 (1H, dd, J=10Hz and J= 7Hz), 4.30 (1H, dd, J= 10Hz and J=7Hz), 6.80-7.35 (7H, m), 9.02 (1H, br s), 9.53 (1H, br s).

5

Example 8**(±) *cis*-1-Amino-2-(3,4-dichlorophenoxy)methyl)cyclopentane Hydrochloride (E8)**

- A solution of (±) *cis*-1-amino-2-hydroxymethylcyclopentane (0.67g, 5.82mmol) in dry dimethyl sulfoxide (20ml), was treated with sodium hydride (0.21g of an 80% dispersion in oil; 7.0mmol). After stirring for 3.25h at room temperature under argon 1,2-dichloro-4-fluorobenzene (0.83ml, 7.0mmol) was added dropwise. After stirring at room temperature for 24h the mixture was quenched at ice temperature with glacial acetic acid (0.4ml) and then worked up as described in Example 5. Purification by chromatography on silica gel eluting with 0-20% methanol in diethyl ether afforded a light brown oil (1.15g).
- 15 Extraction into a mixture of diethyl ether and hexane followed by treatment with ethereal HCl produced the hydrochloride salt which was recrystallised to give the title compound as a colourless solid. m.p. 264-265 °C (dec) (from methanol/diethyl ether).
- ¹H Nmr (DMSO-d₆) δ: 1.46-2.10 (6H, m), 2.45 (1H, m), 3.60 (1H, m), 4.02 (1H, dd, J=10Hz and J=8Hz), 4.14 (1H, dd, J=10Hz and J=8Hz), 7.00 (1H, dd, J=8Hz and J=2Hz),
- 20 7.26 (1H, d, J=2Hz), 7.55 (1H, d, J=8Hz), 8.19 (3H, br s).

Example 9**(±) *cis*-1-Amino-2-[4-(4-fluorophenoxy)phenoxy)methyl]cyclopentane hydrochloride**

- 25 A solution of (±) *cis*-1-amino-2-hydroxymethylcyclopentane (0.46g, 4.0mmol) in dry dimethyl sulfoxide (12ml), was treated with sodium hydride (0.144g of an 80% dispersion in oil; 4.8mmol). After stirring for 3h at room temperature under argon a solution of bis-(4-fluorophenyl)-ether (1.65g, 8.0mmol) in dimethyl sulfoxide (2ml) was added. The mixture was heated to 60°C and held at this temperature for 19h. The reaction was
- 30 quenched at ice temperature with glacial acetic acid (0.27ml, 4.8mmol) and then worked up as described in Example 5. Purification by chromatography on silica gel eluting with 0-5% ethanol in diethyl ether afforded an oil. The product was extracted into diethyl ether-hexane, and insoluble impurities were discarded. Treatment with ethereal HCl produced the hydrochloride salt which was crystallised to give the title compound as a white solid
- 35 (0.56g) m.p. 170-171 °C (from methanol/diethyl ether).
- ¹H Nmr (DMSO-d₆) δ: 1.50-2.10 (6H, m), 2.47 (1H, m), 3.63 (1H, m), 3.97 (1H, m), 4.12 (1H, m), 6.96 (6H, m), 7.18 (2H, m), 8.18 (3H, br s)

Example 10**(±) cis -1-Amino-2-[4-(1-methyl-1-phenylethyl)phenoxyethyl]cyclopentane hydrochloride**

- 5 A mixture of (±) cis 1-[4-(1-methyl-1-phenylethyl)phenoxyethyl]-2-phthalimidocyclopentane (0.75g, 1.70mmol), hydrazine hydrate (0.25g, 5.1mmol), 2-propanol (25ml) and methanol (25ml) was heated at reflux under argon for 18h. The reaction was concentrated *in vacuo* and the residue was partitioned between saturated sodium hydrogen carbonate (20ml) and dichloromethane (20ml). The aqueous layer was
- 10 further extracted with dichloromethane (2x20ml) and the combined organic layers were dried over sodium sulfate and concentrated *in vacuo*. Purification by column chromatography on silica gel eluting with 5% methanol in dichloromethane afforded an oil (0.35g) which was converted into the hydrochloride salt and crystallised to give the title compound as a pale yellow solid m.p. 153-156°C (from methanol/diethyl ether).
- 15 ¹H Nmr (DMSO-d₆) δ: 1.50-2.10 (6H, s and 6H, m), 2.45 (1H, m), 3.60 (1H, m), 3.96 (1H, m), 4.08 (1H, m), 6.85 (2H, d, J = 9Hz), 7.06-7.32 (7H, m), 8.10 (3H, br s).

Example 11

- 20 **(±) cis 1-Methylamino-2-[4-(1-methyl-1-phenylethyl)phenoxyethyl]cyclopentane hydrochloride**

- To a suspension of lithium aluminium hydride (0.205g, 5.38mmol) in dry diethyl ether (10ml) under argon was added dropwise a solution of (±) cis-1-ethoxycarbonylamino-2-[4-(1-methyl-1-phenylethyl)phenoxyethyl] cyclopentane (0.41g, 1.08mmol) in dry
- 25 diethyl ether (15ml). After stirring overnight at room temperature the reaction was worked up as described in Example 7 to give a colourless oil (0.34g) which was converted into the hydrochloride salt and crystallised twice to give the title compound as a colourless solid (0.27g) m.p. 129-131 °C (from acetone/diethyl ether).
- ¹H Nmr (DMSO-d₆) δ: 1.50-1.90 (6H, s and 5H, m), 2.02 (1H, m), 2.57 (3H, s and 1H, m), 3.50 (1H, m), 3.98 (1H, m), 4.12 (1H, m), 6.88 (1H, d, J = 9Hz), 7.08-7.30 (7H, m), 8.90 (2H, br d)
- 30

Example 12

- 35 **(±) cis -1-Amino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxyethyl]cyclopentane hydrochloride**

A mixture of (±) cis-1-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxyethyl]-2-phthalimido cyclopentane (1.5g, 3.28mmol), hydrazine hydrate (0.50g, 9.8mmol), 2-propanol (20ml) and methanol (50ml) was heated at reflux under argon for 24h. The

reaction was worked up as described in Example 10. Purification by column chromatography on silica gel eluting with 10-20% methanol in ethyl acetate afforded a colourless oil (0.78g) which crystallised on cooling. Treatment with ethereal HCl afforded the title compound as a white solid m.p. 164.5-165.5 °C (from methanol/diethyl ether)

- 5 ¹H Nmr (DMSO-d₆) δ: 1.50-2.05 (6H, s, and 6H, m), 2.48 (1H, m), 3.60 (1H, m), 3.98 (1H, m), 4.10 (1H, m), 6.88 (2H, d, J=9Hz), 7.00-7.30 (6H, m), 8.18 (3H, br s).

Example 13


- 10 **(±) cis -1-Methylamino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxyethyl] cyclopentane hydrochloride**

To a suspension of lithium aluminium hydride (0.29g, 7.7mmol) in dry diethyl ether (10ml) under argon was added dropwise a solution of (±) cis-1-ethoxycarbonylamino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxyethyl] cyclopentane (0.62g, 1.55mmol) in dry diethyl ether (15ml). After stirring overnight at room temperature the reaction was worked up as described in Example 7 to give an oil which was converted into the hydrochloride salt and crystallised to give the title compound as a white solid (0.49g) m.p. 160-161 °C (from methanol/diethyl ether).

- 15 ¹H Nmr (DMSO-d₆) δ: 1.50-1.90 (6H, s and 5H, m), 2.00 (1H, m), 2.54 (3H, s and 1H, m), 3.52 (1H, m), 3.92 (1H, m), 4.14 (1H, m), 6.90 (2H, d, J=9Hz), 7.00-7.30 (6H, m), 8.98 (2H, br d).
- 20

Claims

1. The use of a compound of formula (I) :



Formula (I)

wherein

X represents O, S, C=O or a bond;

p and q independently represent 0-4;

- 10 R¹ and R² each independently represent hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl or C₃₋₆cycloalkylC₁₋₄alkyl;

n is 1, 2, 3 or 4; and

Ar represents phenyl optionally substituted by 1 to 3 substituents selected from :


halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₂alkylenedioxy, trifluoromethyl, trifluoromethoxy, CN,

- 15 NO₂, amino, mono- or di- alkylamino and Ph(Alk¹)_rY(Alk²)_s- where Ph is optionally substituted phenyl, Y is a bond, oxygen or a carbonyl group, Alk¹ and Alk² independently represent C₁₋₄alkyl which may be straight or branched and r and s are independently 0 or 1, provided that the length of (Alk¹)_rY(Alk²)_s does not exceed 5 atoms;
- 20 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disorder wherein a calcium channel antagonist is indicated.

2. Use according to claim 1 wherein the disorder is a condition or disease related to an accumulation of calcium in the brain cells of a mammal.

- 25 3. Method of treatment of a condition or disease related to the accumulation of calcium in the brain cells of a mammal which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

- 30 4. A compound of formula (IA):



Formula (IA)

wherein

X represents O, S, C=O or a bond;

5 p and q independently represent 0-4;

R¹ and R² each independently represent hydrogen, C₁₋₆alkyl C₃₋₆cycloalkyl or C₃₋₆cycloalkylC₁₋₄alkyl;

n is 1, 2, 3 or 4; and

Ar represents phenyl optionally substituted by 1 to 3 substituents selected from :

10 halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₂alkylenedioxy, trifluoromethyl, trifluoromethoxy, CN, NO₂, amino, mono- or di- alkylamino and Ph(Alk¹)_rY(Alk²)_s- where Ph is optionally substituted phenyl, Y is a bond, oxygen or a carbonyl group, Alk¹ and Alk² independently represent C₁₋₄alkyl which may be straight or branched and r and s are independently 0 or 1, provided that the length of (Alk¹)_rY(Alk²)_s does not exceed 5 atoms, or a salt thereof;

15 provided that:

when X is O and p and q are 0, Ar is not phenyl substituted by fluorophenoxy, chloro or methyl and when X is a bond and the sum of p and q is 1, Ar is not unsubstituted phenyl, or phenyl substituted by amino, methoxy, methyl or dimethylamino.

20 5. A compound according to claim 4 wherein Ar represents phenyl substituted by a group Ph(Alk¹)_rY(Alk²)_s-.

6. A compound according to claim 5 wherein the sum of r and s is zero or 1.

25 7. A compound according to claim 5 or claim 6 wherein Alk¹ and Alk² independently represent CH₂, C(H)CH₃, or C(CH₃)₂.

8. A compound according to any of claims 4 to 6 wherein Alk¹ and Alk² independently represent a straight chain C₁₋₄alkyl group, provided that the total number of carbon atoms in Alk¹ and Alk² does not exceed 4.

30

9. A compound according to any of claims 4 to 8 wherein n represents 2.

10. A compound according to any of claims 4 to 9 wherein X represents a

bond or oxygen atom.

11. A compound according to any of claims 4 to 10 wherein R¹ and R² independently represent hydrogen or methyl.

5


12. A compound of formula (I) selected from :

- (±) *cis*-1-methylamino-2-(4-benzyloxyphenoxy)cyclopentane;
 - (±) *trans*-1-methylamino-2-(4-benzyloxyphenoxy)cyclopentane;
 - (±) *cis*-1-methylamino-2-(4-benzyloxybenzyl)cyclopentane;
 - 10 (±) *cis*-1-amino-2-(4-benzyloxybenzyl)cyclopentane;
 - (±) *cis*-1-amino-2-(4-benzoylphenoxymethyl)cyclopentane;
 - (±) *cis*-1-amino-2-(4-benzylphenoxymethyl)cyclopentane;
 - (±) *cis*-1-methylamino-2-(4-benzylphenoxymethyl)cyclopentane;
 - (±) *cis*-1-amino-2-(3,4-dichlorophenoxymethyl)cyclopentane;
 - 15 (±) *cis*-1-Amino-2-[4-(4-fluorophenoxy)phenoxymethyl]cyclopentane;
 - (±) *cis*-1-Amino-2-[4-(1-methyl-1-phenylethyl)phenoxymethyl]cyclopentane;
 - (±) *cis*-1-Methylamino-2-[4-(1-methyl-1-phenylethyl)phenoxymethyl]cyclopentane;
 - (±) *cis*-1-Amino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxymethyl]cyclopentane;
 - (±) *cis*-1-Methylamino-2-[4-(1-(4-fluorophenyl)-1-methylethyl)phenoxymethyl]-
 - 20 cyclopentane;
- or a salt thereof.

13. Use as a therapeutic agent of a compound of formula (IB) which is defined as formula (I) with the proviso that when X is O and p and q are 0, Ar is not
 25 phenyl substituted by chloro or methyl and when X is a bond and the sum of p and q is 1, Ar is not unsubstituted phenyl, or phenyl substituted by amino, methoxy, methyl or dimethylamino.

14. A process for the preparation of a novel compound of formula (I) which
 30 comprises :


- (a) to prepare a compound of formula (I) wherein X is O and p and q are both 0, reaction of a compound of formula (II):



Formula (II)

5 wherein n and Ar are as hereinbefore defined with a compound R^1R^2NH wherein R^1 and R^2 are as hereinbefore defined;

(b) to prepare a compound of formula (I) wherein R^1 and R^2 are both hydrogen, reduction of a compound of formula (III):




Formula (III)

10

wherein n, p, q, X and Ar are as hereinbefore defined and R^3 is C_{1-4} alkyl or phenyl C_{1-4} alkyl (e.g. benzyl);

(c) to prepare a compound wherein X is O or S reaction of a compound of formula (IV):




Formula (IV)

15

wherein R^1 , R^2 , p and n are as hereinbefore defined and X^1 is O or S, with a compound of formula $L(CH_2)_qAr$ wherein L is a leaving group and q and Ar are as hereinbefore defined;

20 (d) reaction of a compound formula (V):



Formula (V)

wherein R^1 , R^2 , p and n are as hereinbefore defined and L^1 is a group displaceable by a nucleophile, with a compound $HX(CH_2)_qAr$ wherein X , q and Ar are as hereinbefore defined;

5

(e) interconversion of a compound of formula (I) to a different compound of formula (I), e.g.

- (i) where one of R^1 and R^2 is hydrogen and the other is alkyl, conversion to a compound of formula (I) wherein R^1 and R^2 are both alkyl, or
- 10 (ii) where R^1 and R^2 are both hydrogen, conversion to a compound of formula (I) where at least one of R^1 and R^2 represent alkyl;
- (iii) conversion of a benzoyl substituent in the group Ar to benzyl or to 1-methyl-1-phenylethyl;

and optionally after any of the above processes, forming a salt of formula (I).

15

15. A pharmaceutical composition comprising a compound of formula (IB) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 95/00964		
A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07C217/52 C07C217/54 C07C323/26 C07C225/20 C07C211/40 A61K31/13 A61K31/135		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07C A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 6, 1963 pages 579-583, BELLEAU, B. ET AL. 'Conformation of N-(-chloroethyl)-2-phenoxyethylamines in Relation to Adrenergic Blocking Activity' See compounds VIII, IX, XXIV and XXVI ---	4,9-11
X	RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 7, 1993 pages 1-5, ANCHISI, C. ET AL. 'An Investigation into the Electron-ionization-induced Mass Spectrometric Behaviour of some trans- and cis-Substituted Cycloalkylamines of Pharmaceutical Interest' See compounds 1, 2, 5 and 6 --- <div style="text-align: center;">-/--</div>	4,9,11, 15
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">10 July 1995</div>		Date of mailing of the international search report <div style="text-align: center;">- 1. 08. 95</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer <div style="text-align: center;">Janus, S</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/00964

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 339 600 (WARNER LAMBERT CO) 2 November 1989 ---	1-15
P,X	WO,A,95 04028 (SMITHKLINE BEECHAM PLC ;HARLING JOHN DAVID (GB); ORLEK BARRY SIDNE) 9 February 1995 see the whole document ---	1-15
P,X	WO,A,95 04027 (SMITHKLINE BEECHAM PLC ;HARLING JOHN DAVID (GB); ORLEK BARRY SIDNE) 9 February 1995 see the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/00964

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 3 relates to a method of treatment of the human/animal body. In addition, claim 13 can be interpreted relating to such a method. A search has nevertheless been carried out and was based on the alleged effects of the compounds of the formula (I).
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/00964

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0339600	02-11-89	US-A- 4837226 JP-A- 2011543	06-06-89 16-01-90
WO-A-9504028	09-02-95	AU-B- 7532094	28-02-95
WO-A-9504027	09-02-95	AU-B- 7229394	28-02-95